Gilead Sciences reports its third quarter earnings on Tuesday, October 29, 2013, and the consensus earnings per share estimate is 48 cents per share.
The consensus estimate has fallen over the past three months, from 49 cents. For the fiscal year, analysts are projecting earnings of $1.90 per share. Revenue is projected to be 12% above the year-earlier total of $2.43 billion at $2.72 billion for the quarter. For the year, revenue is projected to roll in at $10.80 billion.
The company has seen steady earnings for the last eight quarters, and for the last four, net income has increased year-over-year by an average of 21%. The company benefited from the boost in the first quarter when profit swelled 63%, marking the biggest gain.
The majority of analysts (89%) rate Gilead as a buy. This compares favorably to the analyst ratings of nine similar companies, which average 42% buys.
Earnings estimates provided by Zacks.
Narrative Science, through its proprietary artificial intelligence platform, transforms data into stories and insights.
from Forbes.com: Most popular stories http://www.forbes.com/sites/narrativescience/2013/10/25/gilead-sciences-expections-down/
ليست هناك تعليقات:
إرسال تعليق